Loading...
When AZT/3TC (Combivir) was released in 1997 as the first coformulated HIV medication, some providers doubted whether it would catch on. After all, the pill burden was reduced only from two pills twice daily to one pill twice daily, and the components of Combivir were, of course, the same as the drugs administered individually. Despite the skepticism, however, Combivir proved to be enormously popular among patients and providers alike, a phenomenon that has since been repeated with coformulated AZT/3TC/abacavir (Trizivir), lopinavir/ritonavir (Kaletra), tenofovir/FTC (Truvada), and abacavir/3TC (Epzicom). Patients not only love the reduced pill burden of these coformulations but also cite reduced pharmacy co-pays as another major plus. Oddl…